Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.

IF 20.3 1区医学 Q1 RHEUMATOLOGY

Annals of the Rheumatic Diseases Pub Date : 2025-06-18 DOI:10.1016/j.ard.2025.05.013

Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B Gottlieb, Richard B Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B M Landewé

引用次数: 0

查看原文本刊更多论文

Bimekizumab治疗活动性银屑病关节炎生物DMARD-naïve患者的勘误表：来自III期随机、安慰剂对照、主动参考BE OPTIMAL研究的52周疗效和安全性结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of the Rheumatic Diseases 医学-风湿病学

CiteScore

35.00

自引率

9.90%

发文量

3728

审稿时长

1.4 months

期刊介绍： Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.